Loading…
Company reports successful outcomes from AI-driven drug discovery collaboration.
NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), announced positive results from Phase III of its AI-driven drug discovery program in collaboration with Yuva Biosciences. The announcement was made following the completion of the trial phase.
The successful outcomes indicate significant progress in the drug discovery process, though specific data points and next steps were not detailed in the announcement.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.